Q2 Earnings Estimate for EPRX Issued By HC Wainwright

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 earnings per share estimates for Eupraxia Pharmaceuticals in a note issued to investors on Thursday, June 26th. HC Wainwright analyst B. Folkes expects that the company will post earnings per share of ($0.21) for the quarter. HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Eupraxia Pharmaceuticals' current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals' Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.79) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.05) EPS and FY2029 earnings at ($0.29) EPS.

Separately, Canaccord Genuity Group initiated coverage on shares of Eupraxia Pharmaceuticals in a research note on Monday, June 16th. They issued a "speculative buy" rating for the company. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $11.00.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX opened at $5.30 on Monday. The firm has a market cap of $190.59 million, a price-to-earnings ratio of -6.97 and a beta of 0.66. Eupraxia Pharmaceuticals has a fifty-two week low of $2.20 and a fifty-two week high of $5.43. The firm has a 50 day moving average price of $4.00 and a 200-day moving average price of $3.57.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in Eupraxia Pharmaceuticals during the 4th quarter valued at $31,000. Raymond James Financial Inc. purchased a new stake in shares of Eupraxia Pharmaceuticals during the fourth quarter worth about $37,000. Bank of Montreal Can boosted its holdings in shares of Eupraxia Pharmaceuticals by 15.2% during the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock worth $178,000 after purchasing an additional 7,500 shares during the period. Royal Bank of Canada grew its stake in shares of Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company's stock worth $1,125,000 after purchasing an additional 59,683 shares during the last quarter. Finally, Scotia Capital Inc. grew its stake in shares of Eupraxia Pharmaceuticals by 11.6% in the first quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company's stock worth $5,072,000 after purchasing an additional 160,960 shares during the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.